Vaccines

Journal Browser

► Journal Browser

Special Issue Editors

Prof. Dr. Chenguang Shen

E-Mail Website
Guest Editor

Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China
Interests: development of therapeutic antibodies and vaccines against important human diseases

Dr. Yang Yang

E-Mail Website
Guest Editor

Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China
Interests: surveillance and humoral immunity investigation of important human diseases

Dr. Minghui Yang

E-Mail Website
Guest Editor

Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Advanced Research Institute of Multidisciplinary Sciences, Beijing Institute of Technology, Beijing, China
Interests: development and identification of RNA vaccine

Special Issue Information

Dear Colleagues,

Vaccination is one of the most economical and effective strategies for the prevention and control of important human diseases. The specific antibody response induced by vaccination is an important mechanism for the vaccine to exert its effect. The diversity of strength, breadth and persistence of the antibody response induced by different types of vaccines determine the protective efficacy of each vaccine. The redesign of vaccines via immunological methods can improve the antibody response induced by vaccines; for example, it can improve the immunogenicity of a certain vaccine through the design of virus-like particles, enhance the broadly neutralizing antibody response through the modification of glycosylation on the antigens, improve the immune recognition of the vaccine through the design of new adjuvants, and improve the stability and delivery efficiency of the mRNA vaccines. This Special Issue covers the design of novel vaccines that can induce highly effective antibody responses, including vaccines against various human infectious diseases and tumors, as well as the isolation, screening and identification of monoclonal antibodies induced by these vaccines. This Special Issue will provide important information for the development of vaccines with favorable efficacy against various human diseases.

Prof. Dr. Chenguang Shen
Dr. Yang Yang
Dr. Minghui Yang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

vaccine design
antibody response
immunological methods
human infectious diseases
tumors
monoclonal antibodies

Published Papers (2 papers)

Download All Papers

Research

Jump to: Review

12 pages, 1881 KiB

Open AccessArticle

Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein

by Jinhu Liang, Linlin Zhai, Zuxin Liang, Xiaoling Chen, Yushan Jiang, Yuanlong Lin, Shiyan Feng, Yingxia Liu, Wei Zhao and Fuxiang Wang

Vaccines 2024, 12(1), 19; https://doi.org/10.3390/vaccines12010019 - 23 Dec 2023

Viewed by 1333

Abstract

Multitudinous broadly neutralizing antibodies (bNAbs) against HIV-1 have been developed as novel antiviral prophylactic and therapeutic agents. Combinations of bNAbs are generally even more effective than when they are applied individually, showing excellent neutralization coverage and limiting the emergence of escape mutants. In this study, we investigated the design and characterization of three trispecific antibodies that allow a single molecule to interact with independent HIV-1 envelope determinants—(1) the host receptor CD4, (2) the host co-receptor CCR5 and (3) distinct domains in the envelope glycoprotein of HIV-1—using an ELISA, an HIV-1 pseudovirus neutralization assay and in vivo antiviral experiments in humanized mice. We found that trispecific bNAbs and monovalent ones all had satisfactory binding activities against the corresponding antigens in the ELISA, exhibited higher potency and breadth than any previously described single bnAb in the HIV-1 pseudovirus neutralization assay and showed an excellent antiviral effect in vivo. The trispecific antibodies simultaneously recognize the host receptor CD4, host co-receptor CCR5 and HIV-1 envelope glycoprotein, which could mean they have promise as prophylactic and therapeutic agents against HIV-1. Full article

(This article belongs to the Special Issue Vaccinal Antibodies: Immunological Methods to Induce Antibody Response)

► Show Figures

Figure 1

Review

Jump to: Research

18 pages, 1143 KiB

Open AccessReview

Anti-Idiotypic mRNA Vaccine to Treat Autoimmune Disorders

by Sarfaraz K. Niazi

Vaccines 2024, 12(1), 9; https://doi.org/10.3390/vaccines12010009 - 21 Dec 2023

Viewed by 1775

Abstract

The 80+ existing autoimmune disorders (ADs) affect billions with little prevention or treatment options, except for temporary symptomatic management, leading to enormous human suffering and a monumental financial burden. The autoantibodies formed in most ADs have been identified, allowing the development of novel anti-idiotypic antibodies to mute the autoantibodies using vaccines. Nucleoside vaccines have been successfully tested as antigen-specific immunotherapies (ASI), with mRNA technology offering multi-epitope targeting to mute multiple autoantibodies. This paper proposes using mRNA technology to produce anti-idiotypic antibodies with broad effectiveness in preventing and treating them. This paper delves into the state-of-the-art mRNA design strategies used to develop novel ASIs by selecting appropriate T cell and B cell epitopes to generate anti-idiotypic antibodies. The low cost and fast development of mRNA vaccines make this technology the most affordable for the global control of ADs. Full article

(This article belongs to the Special Issue Vaccinal Antibodies: Immunological Methods to Induce Antibody Response)

► Show Figures